Governor JB Pritzker credits GLP-1 medication for an 80-pound weight loss, highlighting the growing national reliance on the drug class for managing obesity-related health conditions.
When Illinois Governor JB Pritzker sat down for an interview this September. he spoke with the candor of a man who had fundamentally altered his health trajectory. Since the spring of 2024. the 61-year-old governor has lost 80 pounds. a transformation he attributes to a combination of diet. exercise. and a GLP-1 medication. It was a journey that began with a diagnosis of prediabetes and accelerated after he was diagnosed with Type 2 diabetes. a condition that originally required insulin. Today. nine months after he stopped taking insulin entirely. Pritzker reports his blood sugar levels have returned to normal. and he intends to continue his weight-loss progress.
His decision to go public stems from an awareness that millions of Americans are currently grappling with the same obesity-related health challenges. While his disclosure arrives in a politically charged climate—preceding a period where Democrats are expected to signal their presidential intentions—Pritzker has maintained his focus remains firmly on his bid for a third gubernatorial term this November.
GLP-1 receptor agonists. such as Ozempic. Wegovy. and Zepbound. were initially developed to manage blood sugar for Type 2 diabetes patients. but they have increasingly become a tool for treating obesity. Eligibility for the drugs typically requires a BMI of 30 or higher. though individuals with a BMI of 27 or above may qualify if they suffer from hypertension. high cholesterol. sleep apnea. liver disease. polycystic ovary syndrome. or weight-related anxiety. Clinical guidelines also extend potential eligibility to those who are prediabetic. or who have a history of strokes. heart attacks. or arterial blockages. For those considered overweight—a category generally defined as a BMI of 25 to 29.9—providers may prescribe the drugs if weight loss is deemed necessary to manage coexisting health conditions. Notably, for Asian patients, the risk profile shifts, with health issues increasing at a BMI of 23 or higher.
The accessibility of these treatments often hinges on a complex landscape of insurance coverage. While most plans cover the drugs for Type 2 diabetes, they frequently deny coverage for weight loss alone. In Illinois. the state expanded its group health insurance program in July 2023 to include coverage for injectable weight-loss drugs for eligible state workers. a policy that cost the state $147 million in fiscal year 2025. Cathy Kwiatkowski. a spokesperson for the Illinois Department of Central Management Services. noted that the state sees the expense as a long-term investment in preventing health complications. Under that program. enrollees must participate in a “lifestyle management program” and have their medication deemed medically appropriate by a physician. In contrast, Illinois Medicaid covers GLP-1s strictly for Type 2 diabetes, excluding weight loss.
For patients without insurance coverage, the financial barrier is significant. While list prices for drugs like Ozempic can reach $1. 027.51. pharmaceutical companies offer lower out-of-pocket options; Novo Nordisk provides the Wegovy pill for $149 to $299 per month. or an injectable pen for up to $399. Eli Lilly’s Zepbound ranges from $299 to $449 per month depending on the dosage.
Behind these numbers lies a landscape of genuine medical risk. Experts from institutions including the Cleveland Clinic. Mayo Clinic. and Stanford warn against using GLP-1s if a patient has a history of medullary thyroid carcinoma. multiple endocrine neoplasia type 2. or disordered eating. Pregnancy and breastfeeding are also contraindications. Potential side effects range from nausea. vomiting. and diarrhea to more severe risks like pancreatitis and bowel obstructions. with some data suggesting a potential increase in depression and suicide risk. Furthermore. as research is still ongoing—with the first FDA approval for this drug class only dating back to 2005—the long-term impact on the human body remains an open question.
The rapid rise in popularity—with nearly 30 million U.S. adults, or 11% of the population, now taking GLP-1s—has fueled a market for illicit, unapproved versions. Illinois Attorney General Kwame Raoul has issued warnings against med spas and online retailers selling compounded drugs not vetted by the FDA. The consequences are playing out in emergency rooms: calls to Illinois poison centers for side effects or overdoses of weight-loss injections have more than doubled in one year. Nationally, the situation is even more stark, with a nearly 1,500% increase in similar calls since 2019. For those navigating this surge, the guidance remains consistent: consult a licensed medical provider and utilize only authorized pharmacies.
JB Pritzker GLP-1 weight loss Ozempic Wegovy Zepbound diabetes healthcare Illinois politics